FinTechFunding

Zelira Therapeutics: Launches Zenivol in Australia

  • Zelira Therapeutics (ZLD) has launched its proprietary cannabinoid medicine, Zenivol, in Australia
  • The company has received approval from the Therapeutic Goods Administration’s (TGA) Special Access Scheme to launch the treatment
  • Zenivol is for patients with chronic insomnia and will be available through Zelira’s distribution partner, Health House
  • This announcement follows a successful clinical trial conducted by the University of Western Australia
  • Zelira is on track to launch five new products across global markets in 2020
  • Company shares are up 10 per cent on the market this morning, trading for 6.6 cents per share
Previous article
Saunders International: Awarded $26M defence contract
Next article
Elevations Credit Union: Selects Temenos Infinity
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

NatWest Group Strengthens Free Investment Guidance Programme

New initiative aims to educate more customers on investing.Highlights: NatWest Group expands free investment guidance programme.Initiative targets educating...
FinTech

Tether Launches New Stablecoin Wallet to Enhance User Experience

This innovative platform aims to improve accessibility for crypto users.Highlights: Tether has introduced a new stablecoin wallet.The wallet...
FinTech

FCA Strengthens Money Laundering Combat with Synthetic Dataset

New collaboration aims to enhance detection capabilities against financial crime.Highlights: FCA partners with Turing Institute to combat money...
FinTech

Spektr Strengthens Compliance Efforts with $20M Funding

Fintech startup Spektr secures $20 million for AI-driven compliance solutions.Highlights: Spektr raises $20 million to enhance its AI...